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Coronary artery disease (CAD) is the leading cause of 
death in America. It happens when the arteries that 
supply blood to cardiac muscle become hardened and 
narrowed. This is due to excessive deposition of 
cholesterol, fatty substances and cellular waste products 
in the inner lining of coronary artery. Such a 
pathological condition, termed atherosclerosis, can 
happen in men and women, particularly at a later age. 










































































lipid  metabolism  and  increased  risk  of  developing  metabolic  syndrome.  Increased  apoD  deposition  is  detectable  in
atherosclerotic lesions of humans with established cardiovascular disease as well as mice with premature atherosclerosis.
Moreover, apoD is associated with anti‐oxidation and anti‐stress activities, contributing to lifespan expansion in fruit flies.





for the risk of atherosclerosis include dyslipidemia, 
hypertension, obesity, diabetes and smoking. These 
factors alone or in combination can hasten the 
progression of atherosclerosis and development of 
CAD. Although progress has been made in elucidating 
the pathophysiology of atherosclerosis, the exact cause 
and mechanism underlying the development of 
atherosclerosis still remain obscure [1-3].  
 
Cholesterol homeostasis plays an important role in 
atherosclerosis. Cholesterol is an essential component 
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synthesis of steroid hormones and bile acids. 
Cholesterol in the body derives from two different 
sources, dietary intake and de novo synthesis in tissue 
such as liver – the major organ for endogenous 
cholesterol supply. Unlike fatty acids and triglyceride, 
cholesterol cannot be catabolized. Excessive cholesterol 
must be rid itself of the body via its transportation to 
liver for biliary excretion. This pathway, termed 
“reverse cholesterol transport”, is facilitated by high-
density lipoprotein (HDL) and is viewed as the primary 
mechanism by which HDL protects against the 
development of atherosclerosis [4-7]. Clinical data and 
preclinical studies have conclusively demonstrated that 
lower HDL levels constitute an independent risk factor 
for coronary artery disease. However, the molecular 
basis underlying the cardioprotective action of HDL 
remains incompletely understood. For better clinical 
management of CAD, further studies are warranted to 
better understand cholesterol metabolism and 
pathogenesis of atherosclerosis.  
 
Apolipoprotein D (apoD) is a component of HDL. Due 
to its relative low abundance in HDL particles, apoD 
has received considerably less attention in the research 
area of HDL-cholesterol metabolism and athero-
sclerosis. Recent data indicate that aberrant apoD 
expression is associated with altered lipid metabolism 
and risk of coronary artery disease. This has spurred us 
to conduct a comprehensive review of apoD function in 
triglyceride and cholesterol metabolism to address the 
question of whether apoD is another significant player 
in the pathogenesis of atherosclerosis.   
 
ApoD production in health and disease  
 
In humans, plasma apoD levels range from 3 to 11 
µmol/L. This level is equivalent to plasma levels 
(4.9±0.5 µmol/L) of apolipoprotein C-III (apoC-III), an 
important player in plasma triglyceride metabolism [8-
11]. However, plasma apoD levels are upregulated 
under certain pathophysiological conditions, such as in 
women with gross cystic disease [12]. ApoD levels are 
also elevated in the brain of subjects with chronic 
schizophrenia and in the prefrontal cortex of patients 
with Alzheimer disease [13-15]. Furthermore, treatment 
with antipsychotic drugs, expecially clozapine, also 
results in elevated apoD expression in rodent brains as 
well as in human plasma [13, 16, 17]. Increased apoD 
production is seen in the rat brain following traumatic 
brain injury [18].  
 
In addition, elevated apoD production is detected in 
liver tumors resected from hepatocellular carcinoma 
[19], as well as in invasive carcinoma of the breast [20, 
21]. Elevated apoD levels are present in cyst fluids of 
women with gross cystic disease of the breast [12]. 
Furthermore, increased apoD levels are also detected in 
the breast nipple aspirate fluid in women with breast 
cancer, but nipple fluid apoD levels do not seem to 
correlate with the stage of the breast cancer disease 
[22]. 
 
Recently, Rickhag et al. [23]  demonstrate in a rat 
model of stroke that apoD is significantly elevated in 
the peri-infarct area during the recovery period. It is 
suggested that upregulated apoD production serves the 
function of transporting cholesterol and phospholipids, 
a remodeling process that is required for the recovery of 
brain injury. Likewise, high apoD protein levels are 
found in patients with failing hearts, compared with 
non-failing control subjects, raising the possibility that 
apoD is potential biomarker in human end-stage heart 
failure [24].  
 
Niemann-Pick Type C (NPC) disease is a human 
neurodegenerative disorder characterized by impaired 
intracellular cholesterol transport [25]. Interestingly, in 
rodent models of the human NPC disease, apoD protein 
levels are markedly elevated by 30-fold in the brain and 
6-fold in plasma, correlating with increased intracellular 
cholesterol storage [26, 27]. These findings implicate 
apoD in the pathogenesis of NPC disease.  
 
In addition to its altered expression in the brain, apoD is 
upregulated in cultured myotubes from patients with 
type 2 diabetes [28]. Likewise, enhanced apoD 
expression is detected in muscle biopsies from patients 
with disuse atrophy, a pathological condition that 
impacts muscle function and activity of daily living 
[29]. Interestingly, the induction of apoD mRNA 
expression is accompanied by a corresponding increase 
in leptin receptor mRNA in the immobilized muscle of 
patients with disuse atrophy. Immunohistochemistry co-
localizes apoD and leptin receptor in the perinuclear 
area in the immobilized muscle fibers [29]. These data 
are consistent with the observation of Liu et al. [30], 
who show that apoD and leptin receptor physically 
interact with each other in the brain. ApoD and leptin 
receptor expression are coordinately regulated in the 
hypothalamus in modulating food intake and energy 
homeostasis in mice. Dissociation of apoD with the 
leptin receptor is linked to the development of obesity 
in leptin receptor-deficient db/db mice [30].  
 
Posttranslational modification of apoD 
 
ApoD possesses two N-glycosylation sites (Asn45 and 
Asn78) [31], both of which are evolutionally conserved  
   






























among species (Fig. 1A). This raises the hypothesis that 
apoD is regulated at the post-translational level. In 
support of this hypothesis, we incubated aliquots of sera 
from normal C57BL/6J mice in the absence and 
presence of peptide:N-glycosidase F (PNGase F), an 
amidase that catalyzes the removal of carbohydrate 
moieties from N-linked glycoproteins. As shown in Fig. 
1B, pre-incubation of plasma apoD with PNGase F 
resulted in apoD de-glycosylation, as evidenced by the 
production of de-glycosylated apoD with reduced 
molecular masses. Likewise, serum apoD as well as 
apoD secreted from axillary glands in humans are also 









































aligned  using  the  ClustalW  program.  Amino  acid  residues  in  box  denote  two  highly  conserved  N‐glycosylation  sites  in  apoD.  The
consensus N‐glycosylation site is Asn‐X‐Ser/Thr. (B) Plasma apoD is N‐glycosylated. Aliquots of plasma (20 µg protein) from C57BL/6J mice
were incubated without (‐) and with (+) 1,000 U of N‐glycosidase F (New England Biolabs) in a total volume of 30 µl at 37°C for 1 hour to





cance of this  post-translational modification remained 
incompletely understood, it is suggested that N-
glycosylation modulates apoD protein folding, resulting 
in conformational changes favorable for binding to its 
physiological ligands or association with HDL. In this 
context, it would be of significance to convert the two 
N-glycosylation sites Asn45 and Asn78 to alanine 
residues in apoD by site-directed mutagenesis. The 
resulting apoD mutants will be ideal molecules for 
determining the physiological impact of N-
glycosylation on the ability of apoD to associate with 
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ApoD is an atypical apolipoprotein of 169 amino acids. 
Unlike canonical apolipoproteins that are produced 
mainly in liver and intestine, apoD is expressed widely 
in mammalian tissues including brain, liver, intestine, 
cardiac and skeletal muscle, adipose tissue, and 
pancreas [34-36] (Fig. 2). ApoD does not share 
significant degrees of homology in the amino acid 
sequence with other apolipoproteins. Instead, apoD  is 
structurally similar to the lipocalin family of proteins. 
This superfamily comprises a diverse class of lipid-
binding proteins including fatty acid binding proteins 
(FABPs), plasma retinol-binding proteins (RBP) and 
apolipoprotein M (apoM) [34, 37-39]. Despite their 
dissimilarities in amino acid sequences, the lipocalin 
superfamily of proteins share a highly conserved β-
barrel structure that is comprised of an eight-stranded 
anti-parallel β-sheet [40]. Such a tertiary architecture is 
predicted to form a ligand-binding pocket that is 
thought for binding and transporting lipids and other 
small hydrophobic molecules [34, 37]. This cha-
racteristic lipocalin fold is validated for apoD by 
Eichinger et al. [41], who recently crystalized the 
human apoD protein in its free form and in complex 
with progesterone. Cystallographic studies reveal that 
the eight-stranded anti-parallel β-sheets of apoD are 
connected by four loops in a pair-wise manner, forming 
a conically shaped cavity that is capable of binding 
hydrophobic ligands [40, 41]. Consistent with its 
structural organization, apoD is shown to associate with 
a number of ligands including cholesterol, progesterone, 


















Circulating ApoD is present mainly in HDL and to a 
lesser extent in LDL and VLDL [42, 43] (Fig. 3). 
Nonetheless, little is known about the role of apoD in 
lipoprotein metabolism and its impact on 
atherosclerosis. Plasma apoD levels are significantly 
reduced in patients with Tangier disease, a rare 
autosomal recessive disorder that is caused by 
mutations in the ATP-binding cassette A1 (ABCA1) 
gene [34, 44]. As ABCA1 plays a key role in effluxing 
cholesterol from cells, ABCA1 loss-of-function results 
in diminished cholesterol removal from peripheral 
tissues, contributing to excessive accumulation of 
cholesterol in the body and increased risk of developing 





























(HF)  for  8  weeks.  Aliquots  of  250‐µl  sera  of  mice  (n=5)  were
fractionated by gel filtration column chromatography. Fractions







Recently, Vaisar et al. [51] took a proteomics approach 
to profile protein composition of HDL particles isolated 
from human subjects. Their studies reveal that HDL 
isolated from healthy individuals versus subjects with 
established CAD carry different protein cargos. 
Interestingly, apoD is highly enriched in HDL isolated 
from seven subjects with CAD, in comparison to six 
healthy controls. This observation seems paradoxical, as 
CAD patients are associated with lower HDL levels and 
apoD is mainly bound to HDL in the circulation. An 
increased apoD content in HDL may present a 
pathological marker or constitute a compensatory 
response to impaired cholesterol metabolism in subjects 
with established CAD.  
Figure 2. Tissue distribution of apoD mRNA expression.
Total RNA was prepared from different tissues of C57BL/6J mice.





To recapitulate this clinical observation, we determined 
plasma apoD expression in normal and atherogenic 
mice with genetic depletion of apolipoprotein E (apoE), 
a commonly used rodent model of atherosclerosis. 
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plasma cholesterol levels and develop atherosclerosis 
with the deposition of fatty streaks in the proximal aorta 
at 3 months of age. We show that plasma apoD levels 
are markedly increased in apoE knockout mice (Fig. 4). 
These results together with clinical data presage a 
















Abnormal apoD production in metabolic 
syndrome   
 
In addition to its role in cholesterol homeostasis, apoD 
is involved in triglyceride metabolism. Epidemiological 
studies identified three distinct missense mutations, 
namely Phe36Val, Tyr108Cys and Thr158Lys in the 
apoD gene in African populations. Each of these three 
mutations is associated with significantly elevated 
plasma triglyceride levels and reduced HDL-cholesterol 
levels, a plasma lipid profile that is characteristic of 
metabolic syndrome [52, 53]. Although the underlying 
molecular basis remains to be defined, these clinical 
data implicate abnormal apoD function in the 
pathogenesis of metabolic syndrome.  
 
Consistent with this idea, two studies demonstrate a 
linkage between the TaqI polymorphism of the apoD 
gene and type 2 diabetes in South Indians and Nauruans 
[54, 55]. Subsequently, Vijayaraghavan et al. [56] 
report that the TaqI polymorphism of apoD is associated 
with the development of obesity, insulin resistance and 
hyperinsulinemia in the British Caucasoid population. 
This effect seems to be independent of body weight, as 
no significant association is detected between the apoD 
polymorphism and body mass index (BMI) or waist to 
hip ratio in the same cohort of subjects [56].  
 
Curry et al. [57] report that plasma apoD levels are 
significantly lower in patients with hyper-
chylomicronemia. In a separate study to identify the 
factors that affect lipids and apolipoproteins at birth, 
Lane et al. [58] show that significant reductions in 
triglyceride and ApoD levels are detected in infants who 
subsequently became ill in the postnatal period with 
problems relating to carbohydrate metabolism (e.g., 
infants of diabetic mothers). Together these clinical data 
suggest that apoD is another significant player in lipid 
metabolism. ApoD dysregulation may contribute to 
metabolic abnormalities in insulin resistant subjects 
with obesity and/or type 2 diabetes.  
 
Further evidence of apoD as a significant player in lipid 
metabolism derives from the studies in obese db/db 
mice. Due to leptin receptor deficiency, db/db mice are 
hyperphagic, developing morbid obesity and type 2 
diabetes at about 12 weeks of age. Interestingly, Liu et 
al. [30] show that apoD and leptin receptor, which are 
co-expressed in the hypothalamus, interact with each 
other in regulating food uptake and body weight gain. 
Hypothalamic apoD mRNA is markedly induced in 
response to high fat feeding. However, this effect is 
abolished with a concomitant reduction of apoD mRNA 
levels in the hypothalamus of obese db/db mice. These 
data suggest that apoD may participate in the regulation 
of food intake and body fat accumulation via cross-






knockout  mice.  Data  were  obtained  from 16‐wk  old  mice.  *P
<0.05 vs. ApoE‐/‐ mice by ANOVA. 
 
ApoD in HDL remodeling 
 
There are two lines of evidences suggesting that apoD 
contributes to HDL remodeling. First, apoD is shown to 
modulate the activity of lecithin:cholesterol 
acyltransferase (LCAT), an HDL-bound enzyme that 
catalyzes the conversion of free cholesterol to 
cholesterol ester that is sequently recruited into the core 
of HDL. This effect along with apolipoprotein E (apoE) 
contributes to HDL core expansion and promotes HDL 
maturation [59]. Albers et al. report that apoD is a 
carrier of lysolecithin, a product of the LCAT reaction 
[60]. This finding is accordance with the observation 
that apoD interacts with LCAT [61]. However, whether 
apoD acts as an activator or inhibitor of LCAT activity 
still remains controversial. Studies by Kostner et al. [62] 
suggest that apoD is an activator of LCAT, which is at 
variance with the data of Albers et al. [63], who show 
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studied the activation of LCAT activity by apoD in 
comparison to apoA-I and apoC-I in reconstituted 
proteoliposomes. ApoA-I is the most potent activator of 
LCAT, followed by apoC-I and apoD. Their studies 
suggest that apoD modulates LCAT activity presumbly 
by stabilizing the enzyme on HDL [64].  
 
Second, apoD contributes to HDL remodeling via its 
covalent cross-link with apolipoprotein A-II (apoA-II), 
a structural component of HDL. Blanco-Vaca et al. [65] 
detect the presence of disulfide-linked heterodimers of 
apoD and apoA-II in human plasma. Non-reducing 
polyacrylamide gel electrophoresis demonstrates that 
the apoD-apoA-II heterodimer has an apparent 
molecular mass of 38 kDa, which is significantly larger 
than monomeric apoD (MW, 29 kDa). Sequence 
analysis reveals the presence of five cysteine residues in 
the human apoD protein. Mass Spectrometric analysis 
in combination with crystallographic studies of human 
apoD protein illustrates that four cysteines (Cys16-
Cys41 and Cys8-Cys114) are primed for forming two 
intra-molecular disulfide bonds and the remaining 
unpaired cysteine (Cys-116) is responsible for inter-
molecular covalent cross-link with Cys-6 of apoA-II 
within HDL [31, 41]. Interestingly, the rodent apoD 
lacks the unpaired Cys-116, as it is replaced by 
threonine at the corresponding amino acid residue. 
Thus, the physiological significance of this covalent 
cross-link between apoD and apoA-II in HDL 
remodeling and cholesterol metabolism remains elusive 
[41].  
 
ApoD in oxidative stress and aging 
 
Increased oxidative stress is closely associated with 
inflammation, insulin resistance, diabetes and 
atherosclerosis. There is accumulating evidence that 
apoD plays an important role in oxidative stress. Do 
Carmo et al. [66] show in cultured NIH/3T3 fibroblasts 
that apoD expression is significantly induced in 
response to cellular stress, regardless of whether the 
stress condition is caused by lipopolysaccharide (LPS) 
stimulation, H2O2 treatment or UV-light irradiation. 
This effect seems to be mediated by the NF-kB 
pathway, as there are several conserved NF-kB binding 
sites in the apoD promoter [66]. Furthermore, Do 
Carmo et al. [67] show that apoD confers a 
neuroprotective effect in the brain of mice. Their studies 
demonstrate that mice over-expressing human apoD in
 
neurons, as opposed to normal controls, are more 
resistant with a 3-fold higher survival rate in response to 
human coronavirus-induced acute encephalitis. 
Likewise, Ganfornina et al. [68] show that apoD 
overexpression in the brain protects mice from 
oxidative stress. This effect correlates with the ability of 
apoD to prevent lipid peroxidation in cells [68].  
 
Additional evidence of apoD function against oxidative 
stress stems from studies in fruit flies. Sanchez et al. 
[69] show that genetically modified Drosophila mutants 
with loss-of-function of the human apoD homolog gene 
(GLaz) exhibit high sensitivity to oxidative stress and 
nutrient deprivation. The GLaz mutant flies also have an 
increased accumulation of lipid peroxidation products in 
the body, accompanied by 10-15% reduction in 
lifespan. Conversely, Walker et al. [70] show that 
Drosophila with overexpression of the apoD homolog 
GLaz  displays enhanced resistance to starvation and 
oxidative stress. ApoD overexpression also ameliorates 
lipid peroxidation with a 30% extension of lifespan in 
flies [70]. Similar observations are made by Muffat et 
al. [71], who demonstrate that overproduction of the 
human apoD are also associated with significantly 
reduced lipid peroxidation products, protecting against 
oxidative stress and extending lifespan by about 40% in 
fruit flies. Together these data demonstrate an 
evolutionally conserved safeguarding mechanism by 
which apoD acts to protect against lipid peroxidation 
and oxidative stress.  
 
Although apoD is shown to confer a significant 
beneficial effect on aging in fruit flies, there is a lack of 
evidence that apoD contributes to lifespan expansion in 
mammals. It is noteworthy that apoD is abundantly 
expressed in the brain. Elderly subjects and patients 
with Alzheimer are associated with markedly elevated 
apoD production in the brain [72-74], but the 
underlying pathophysiology is unknown. It is important 
to understand whether and how apoD affects aging and 
contributes to lifespan expansion in mammals.  
 
Impact of apoD on atherosclerosis 
 
Does apoD contribute to atherosclerosis? To address 
this issue, Sarjeant et al [75] subject thin-sections of 
coronary arteries of archived human specimens to anti-
apoD immunohistochemistry. Their studies visualize an 
increased apoD deposition in atheromatous plaques. 
Consistent with this finding, we show that apoD is 
localized in atherosclerotic lesions of apoE knockout 
mice (Fig. 5). Thus, elevated apoD deposition along 
with excessive cholesterol accumulation is detectable in 
atherosclerotic lesions of both human and rodent 
origins. This is correlated with the ability of apoD to 
bind and transport cholesterol, raising the possibility 
that apoD may play a significant role in the 
pathogenesis of atherosclerosis. It follows that an 
increased deposition of apoD in atherosclerotic lesions 
can derive from a compensatory response of apoD to 
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result from the consequence of defects in apoD-
mediated cholesterol trafficking. Further studies are 
warranted to distinguish whether apoD contributes to or 





































Conclusions and perspectives  
 
ApoD is a 29-kDa glycoprotein of 169 amino acids. 
ApoD is evolutionally conserved among species and is 
expressed in a variety of mammalian tissues. Although 
classifed as apolipoprotein, apoD belongs to the 
lipocalin family due to its structural adoptation of a β-
barrel structure that is characteristic of lipocalins [40, 
41]. ApoD is shown to be a multi-ligand binding protein 
that is capable of transporting small hydrophobic 
molecules such as arachidonic acid, steroid hormones, 
and cholesterol for metabolism or signaling [34]. 
Altered apoD expression has been associated with a 
number of pathological conditions, including breast 
carcinoma, prostate cancer, Parkinson’s disease, 
Alzheimer, schizophrenia, bipolar disorder, etc [13-17, 
34, 72, 74, 76-80]. Elevated apoD deposition is also 
detected in amyloid plaques in the brains of patients 
with Alzheimer with undefined pathophysiology [15, 
79]. These data underscore the importance of apoD in 
the pathophysiology of cancer and neurological 
disorders. However, a comprehensive survey of apoD 
function is beyond the scope of this article. Instead, we 
center our review on apoD in lipid metabolism in 
relation to the pathogenesis of dyslipidemia and 
atherosclerosis, the two intertwined pathological traits 
that consequently predispose an at-risk individual to 
CAD.  
 
ApoD is categorized as apolipoprotein due to its initial 
isolation from human HDL. Indeed, circulating apoD is 
bound mainly to HDL, correlating with the ability of 
apoD to associate via covalent cross-link with apoA-II. 
Plasma apoD is also present at a relatively low content 
in VLDL and LDL, suggesting that apoD plays 
significant roles in both triglyceride and cholesterol 
metabolism. Consistent with this notion, apoD 
polymorphism is associated with lipid disorders, as 
characterized by elevated plasma triglyceride levels 
and/or reduced HDL levels. ApoD is enriched in HDL 
isolated from patients with established CAD. Likewise, 
increased apoD deposition is detected in the 
atherosclerotic plaques of both human and rodent 
origins. However, a cause and effect relationship 
between aberrant apoD production and abnormal 
lipoprotein metabolism remains unknown. For example, 
how do apoD mutations result in elevated plasma 
triglyceride levels? Does apoD affect hepatic VLDL 
production and plasma VLDL clearance? Does apoD 
protect against or contribute to the pathogenesis of 
atherosclerosis? While apoD is present in HDL in 
dimerization with apoA-II, it is not clear how this inter-
molecular cross-link affects HDL remodeling and 
impacts cholesterol metabolism. Obviously, further 
studies are needed to characterize the role of apoD in 
Figure 5. ApoD is localized to atherosclerotic plaques of
apoE‐deficient  mice.  Proximal  aorta  sections  of  male  apoE
knockout mice were subjected to oil red O staining (A), and to
immunohistochemistry using control rabbit IgG against bacterial
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the underlying mechanism that links apoD 
dysregulation to abnormalities in lipoprotein 
metabolism, accounting for heightened risk of 
developing CAD in subjects with obesity and/or 
diabetes.  
 
Equally important, apoD is implicated to play a 
significant role in aging, as elevated apoD production 
results in lifespan extension in Drosophila. Elevated 
apoD production is seen in aging brains and altered 
brain apoD expression is associated with neurological 
disorders. It is of paramount importance to define apoD 
function in the brain and understand the molecular basis 
by which apoD affects aging and contributes 
neurological diseases.  
 
MATERIALS AND METHODS 
 
Analysis of apoD N-glycosylation. Aliquots of plasma 
(20 µg protein) from C57BL/6J mice (male, 10 weeks 
old) were incubated without (-) and with (+) 1,000 U of 
N-glycosidase F (New England Biolabs) in a total 
volume of 30 µl at 37°C for 1 hour. The reaction 
mixture was resolved on 4-20% SDS-polyacrylamide 
gels, followed by immunoblot analysis using polyclonal 
rabbit anti-apoD (developed in our own laboratory).  
 
RNA isolation and RT-PCR assay. Total RNA isolation 
from tissue (20 mg) was performed using the RNeasy 
Mini Kit (QIAGEN, Valencia, CA). Aliquots of purified 
RNA (100 ng) from were subjected to RT-PCR analysis 
using apoD sequence-specific primers  flanking the 
apoD mRNA for forward reaction (5'-
TAAGGCCTCTCCTGCAGCCA-3') and reverse 
reaction (5'-CTTTACAGGAAGTCCGGGCAG-3'). 
The resulting PCR products were resolved on 1% 
agarose gel containing ethidium bromide and visualized 
by UV light. 
 
Immunohistochemistry.  Mice were sacrificed and the 
proximal aorta of individual mice was dissected free of 
adipose and connective tissue, and immediately fixed in 
4% paraformaldehyde. The aorta was mounted in 
Cryomatrix (Shandon, Pittsburgh, PA) and frozen in 
isopentane that has been pre-cooled in liquid nitrogen. 
Transverse cryo-sections (10 µm) were cut and stained 
by oil red O to visualize the atherosclerotic lesions. 
Consecutive sections were immunostained using either 
rabbit control IgG derived against bacterial β-
galactosidase or polyclonal rabbit anti-apoD, followed 
by incubation with the donkey anti-rabbit IgG 
conjugated with Cy3. All animal studies were approved 
by the IACUC of Children’s Hospital of Pittsburgh 
(protocol #30-07).  
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